wjpmr, 2024, 10(8), 71-78

SJIF Impact Factor: 6.842

WORLD JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.wjpmr.com

Review Article

ISSN 2455-3301

WJPMR

A REVIEW ON ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN PRETERM NEONATES

Gauri Vitthal Chavale[1*], Pratiksha Raman Kabde[2], Shrimangale Ayodhya Ramesh[3], Harshdeep Sunil Sapkal[4]

[1,2,3,4] Pharm.D, Swami Ramanand Teerth Marathwada University, Nanded.

***Corresponding Author: Gauri Vitthal Chavale**

Pharm.D, Swami Ramanand Teerth Marathwada University, Nanded.

Email ID: chavalegauri@gmail.com

Article Received on 31/05/2024 **Article Revised on 21/06/2024** **Article Accepted on 11/07/2024**

ABSTRACT

Because of their distinct physiological and developmental traits, preterm newborns with Acute Respiratory Distress Syndrome (ARDS) present considerable hurdles. The epidemiology, pathophysiology, clinical presentation, diagnosis, therapy approaches, and consequences of ARDS, particularly in preterm newborns, are summarized in this review. Important subjects include the unique processes of lung damage, difficulties in obtaining an early diagnosis, breathing systems that are improved, and novel treatments such stem cell-based methods and bioengineered surfactants. Future directions include the use of precision medicine, developments in non-invasive monitoring and imaging methods, and the necessity of multicenter collaborative research to improve knowledge and treatment of this life-threatening illness. This review attempts to direct future activities for improving outcomes and lowering morbidity associated with ARDS in preterm children by addressing gaps in existing research and clinical practice.

KEYWORDS: Acute Respiratory Distress Syndrome, ARDS, preterm infants, neonates, lung injury, ventilation strategies, biomarkers, stem cells, precision medicine, lung imaging.

INTRODUTION

Acute inflammation and pulmonary edema are the hallmarks of the severe and potentially fatal Acute Respiratory Distress Syndrome (ARDS), which significantly impairs gas exchange and causes respiratory failure. Numerous direct or indirect insults to the lung, including pneumonia, sepsis, trauma, or inhaling toxic chemicals, can result in acute respiratory distress syndrome (ARDS). Gaining an understanding of ARDS is essential for enhancing medical care and improving outcomes, especially for vulnerable groups like as preterm neonates.[1,2]

Background of Acute Respiratory Distress Syndrome (ARDS)

Ashbaugh et al. initially defined ARDS as an acute respiratory failure syndrome in 1967. The illness was characterized by widespread pulmonary infiltrates, reduced lung compliance, and refractory hypoxemia. The etiology of acute respiratory distress syndrome (ARDS) entails a multifaceted interaction of inflammatory reactions that culminate in heightened permeability of pulmonary capillaries, therefore filling alveoli with protein-laden edema fluid. Severe hypoxemia is caused by this process, which also compromises gas exchange and disturbs normal lung architecture.

The Berlin Definition's clinical criteria, which include the degree of hypoxemia, the timing of the condition, the source of edema, and imaging results, are used to diagnose ARDS. ARDS is usually managed with supportive care using mechanical breathing techniques, fluid control, and treating the underlying cause.[3,4]

Importance of Studying ARDS in Preterm Neonates

Preterm newborns have a higher chance of getting ARDS because of the immaturity of their immune systems and lungs, especially if they are born before 37 weeks of gestation. Aspiration, pneumonia, newborn sepsis, and other inflammatory diseases are among the causes of ARDS in this group. It is essential to research ARDS in preterm newborns for a number of reasons.

1. **High Vulnerability**: Preterm newborns are more vulnerable to respiratory issues and acute respiratory distress syndrome (ARDS) due to their undeveloped lungs and surfactant insufficiency. Knowing the particulars of ARDS in this population can assist design targeted therapies that will enhance survival and long-term results.
2. **Improving Clinical Management**: It can be difficult to diagnose ARDS in preterm newborns early on, but prompt management is essential. To lower morbidity and death, research in this field can

improve diagnostic standards, find early biomarkers, and create focused treatment plans.

3. **Long-Term Outcomes**: Chronic lung disease and long-term neurodevelopmental deficits are two long-term outcomes of ARDS in premature newborns. Researching the etiology and treatment of ARDS in this demographic might help develop strategies that reduce these negative effects and enhance survivors' quality of life.
4. **Resource Allocation**: Intensive medical treatment, such as mechanical ventilation and specialist neonatal intensive care unit (NICU) resources, are frequently necessary for preterm infants with ARDS. Planning and allocating resources in newborn care settings can be improved by having a better understanding of the epidemiology and risk factors of ARDS in this group.

Because of their high susceptibility, the difficulty of clinical management, the possibility of long-term negative consequences, and the requirement for effective resource usage in newborn care, ARDS in preterm neonates is an important field of research. Improvements in this area might benefit these vulnerable newborns' survival and general health.[5,6]

EPIDEMIOLOGY

One of the biggest challenges in the management of preterm neonates is Acute Respiratory Distress Syndrome (ARDS), especially in those born before 37 weeks of gestation. This fragile group has a variable but considerable prevalence of acute respiratory distress syndrome (ARDS), which accounts for 10% to 20% of instances of acute respiratory failure in neonatal intensive care units (NICUs). The incidence rate varies as well; estimates place the possibility of preterm neonates having ARDS in as many as 5% of all NICU hospitalizations. Due in large part to their underdeveloped lungs and increased vulnerability to respiratory irritants, rates of this occurrence can reach 10% to 15% in extremely preterm children. Neonatal sepsis, congenital pneumonia, and meconium aspiration syndrome are among the conditions that increase the risk and are responsible for ARDS development in a significant number of patients. ARDS continues to be a major cause of morbidity and death in this group despite advancements in newborn care, underscoring the continuous need for specialized therapies and improved preventative methods to improve outcomes for these vulnerable infants.[7,8]

TYPES

Acute Respiratory Distress Syndrome (ARDS) in preterm neonates can have many different forms, which are frequently grouped according to the underlying cause or triggering event.

1. **Primary ARDS**: This type of condition is brought on by an actual damage to the lungs, such as pulmonary bleeding, pneumonia, or meconium aspiration syndrome. These disorders can cause acute inflammation and increased pulmonary vascular permeability in preterm newborns, which can harm the alveoli and cause respiratory distress.
2. **Secondary ARDS**: In preterm newborns, secondary ARDS can arise as a consequence of systemic diseases such as neonatal sepsis, which sets off an inflammatory response in the body that damages the lungs. Widespread inflammation and endothelial dysfunction cause lung edema and poor gas exchange in sepsis-induced acute respiratory distress syndrome (ARDS).
3. **Ventilator-Associated ARDS**: Preterm infants may get ARDS as a result of mechanical ventilation in neonatal critical care units. Barotrauma, volutrauma, or oxygen toxicity can all lead to ventilator-associated ARDS and worsen pre-existing lung immaturity, which in turn increases the risk of respiratory failure.
4. **Late-Onset ARDS**: Some preterm infants may get ARDS later in the neonatal stage. This condition is frequently linked to nosocomial infections, prolonged mechanical ventilation, and prematurity-related problems. In order to avoid respiratory impairment from getting worse, late-onset ARDS presents obstacles for diagnosis and treatment. Vigilant monitoring and quick action are necessary.
5. **Neonatal Respiratory Distress Syndrome (NRDS) Progressing to ARDS**: Hyaline membrane disease, or NRDS, is frequently observed in premature infants as a result of surfactant insufficiency. Severe instances or when aggravating variables are present, ARDS, which is typified by diffuse pulmonary infiltrates, hypoxemia, and increased respiratory distress, can develop from NRDS.[9,10,11]

ETIO-PATHOGENISIS

Acute respiratory distress syndrome (ARDS) in preterm infants is caused by a complicated interplay between inflammation, lung immaturity, and other underlying disorders. The main mechanisms are as follows.

1. **Lung Immaturity**: Preterm newborns are born with undeveloped lungs, which are indicated by immature alveolar epithelial cells and inadequate surfactant synthesis. This makes them more susceptible to lung damage and predisposes them to respiratory distress even in normal circumstances.
2. **Inflammatory Response**: In preterm newborns, an injury to the lungs, such as sepsis, pneumonia, or meconium aspiration, frequently triggers the onset of ARDS. This sets off a localized inflammatory response that involves the migration of inflammatory cells (macrophages and neutrophils) into the lung tissue as well as the production of pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1, and interleukin-6).
3. **Increased Capillary Permeability**: Cell damage and inflammatory mediators cause the pulmonary capillaries to become more permeable. Due to the leakage of fluid, proteins, and inflammatory cells

into the alveolar spaces, gas exchange is hampered and alveolar edema results.

4. **Endothelial and Epithelial Injury**: Direct damage to endothelial cells lining capillaries and epithelial cells lining alveoli compromises the integrity of the alveolar-capillary barrier. This damage interferes with the normal function of the barrier, which exacerbates alveolar flooding and reduces lung compliance.
5. **Oxidative Stress and Cell Damage**: The lung tissue may experience oxidative stress as a result of inflammatory processes and the presence of active neutrophils. Oxidative stress produces reactive oxygen species (ROS), which can harm cellular membranes, worsening lung injury and escalating inflammation.
6. **Surfactant Dysfunction**: Surfactant deficit or dysfunction is a common occurrence in preterm newborns, especially in circumstances such as Neonatal Respiratory Distress Syndrome (NRDS). Surfactant is essential for preserving alveolar stability, lowering surface tension inside the alveoli, and averting collapse. Insufficient surfactant exacerbates lung compliance in ARDS and raises the likelihood of atelectasis.
7. **Progression to Fibrosis**: There is a chance that ARDS that is severe and persistent will advance to fibrosis. Long-term respiratory consequences can be exacerbated by the deposition of collagen and fibrotic tissue in the lungs due to persistent inflammation and tissue healing processes.

Understanding these mechanisms is essential for the management and treatment of ARDS in preterm neonates, emphasizing strategies that aim to mitigate inflammation, support lung function, and promote recovery of lung tissue integrity to improve outcomes in this vulnerable population.[12,13,14]

CLINICAL PRESENTATIONS[14,15]

Clinical Feature
Respiratory Distress
Cyanosis
Tachypnea
Hypoxemia
Acidosis
Decreased Breath Sounds
Chest X-ray Findings
Poor Perfusion
Hypotension
Altered Mental Status
Increased Oxygen Requirements
Apnea
Nasal Flaring
Grunting
Pallor

DIAGNOSIS[16,17]

Diagnostic Aspect	Details
Clinical Assessment	
- History and Physical Examination	Assess for signs of respiratory distress: tachypnea, nasal flaring, grunting, retractions.
- Gestational Age and Birth History	Higher risk in infants born before 32 weeks of gestation.
Laboratory Tests	
- Arterial Blood Gas (ABG) Analysis	Measure PaO2, PaCO2, and pH to assess oxygenation and ventilation status.
- Complete Blood Count (CBC)	Assess for signs of infection.
- Blood Cultures	Rule out sepsis or other systemic infections.
Imaging Studies	
- Chest X-ray	Look for diffuse ground-glass opacities, bilateral infiltrates, air bronchograms, reduced lung volumes.
Diagnostic Criteria	
- Acute Onset	Symptoms of respiratory distress present within hours after birth.
- Chest Imaging	Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules.
- Oxygenation	Adjusted PaO2/FiO2 ratio or oxygenation index (OI):
- Mild ARDS	OI between 4 and 8.
- Moderate ARDS	OI between 8 and 16.
- Severe ARDS	OI greater than 16.
- Exclusion of Cardiac Failure	Clinical assessment and echocardiography to exclude primary cardiac causes.
Additional Diagnostic Tools	
- Pulse Oximetry	Continuous monitoring of oxygen saturation (SpO2).
- Echocardiography	Evaluate cardiac function, exclude congenital heart defects or pulmonary hypertension.
- Surfactant Levels	Measurement in tracheal aspirates (not routinely performed).

Differential Diagnosis	
- Other Respiratory Conditions	Exclude conditions like TTN, MAS, pneumonia, congenital diaphragmatic hernia, pulmonary hemorrhage.

TREATMENT

Preterm newborns with Acute Respiratory Distress Syndrome (ARDS) have a dangerous disease that has to be treated quickly and effectively. Below is a summary of the main therapeutic approaches.

1. Respiratory Support

- **Mechanical Ventilation**: Frequently employed to supply sufficient ventilation and oxygenation. It is preferable to use gentle breathing techniques to reduce lung damage.
- **Continuous Positive Airway Pressure (CPAP)**: This technique keeps alveoli open and positive pressure in the airways maintained.
- **High-Frequency Oscillatory Ventilation (HFOV)**: In extreme situations, this technique may be utilized to maximize lung damage while increasing oxygenation.

2. Surfactant Therapy

- Surfactant is a chemical that helps keep the alveoli open, and preterm newborns frequently do not have enough of it. It is possible to provide exogenous surfactant to enhance oxygenation and lung function.

3. Oxygen Therapy

- To ensure appropriate oxygenation, more oxygen is given. Vigilant observation is necessary to prevent oxygen poisoning.

4. Fluid Management

- To prevent fluid excess, which can worsen pulmonary edema, precise fluid control is essential. If required, diuretics may be administered.

5. Pharmacological Interventions

- **Corticosteroids**: May be used to reduce inflammation and improve lung function.
- **Antibiotics**: Administered if there is a suspicion of infection.
- **Inhaled Nitric Oxide (iNO)**: Can be used to improve oxygenation in severe cases by reducing pulmonary hypertension.

6. Nutritional Support

- Growth and healing depend on getting enough nourishment. Initial parenteral nutrition may be required, with a shift to enteral feeding as tolerated.

7. Monitoring and Supportive Care

- It is important to continuously check blood gases, vital signs, and other pertinent indicators.
- The provision of sufficient pain treatment, infection prevention, and thermal stability maintenance are all examples of supportive care.

8. Experimental Therapies and Future Directions

- **Stem Cell Therapy**: Investigations exploring the possibility of using stem cells to treat and rebuild lung tissue are still continuing.
- **New Surfactants and Anti-inflammatory Agents**: In an effort to enhance results, novel medications and treatments are constantly being developed.

A multidisciplinary strategy is used to treat ARDS in preterm newborns, with an emphasis on respiratory assistance, surfactant treatment, cautious hydration and nutritional control, continuous monitoring, and supportive care. New treatments have the potential to improve results for this susceptible group.[18,19,20,21]

Drugs used to treat Acute Respiratory Distress Syndrome (ARDS) in preterm infants.[22]

Drug Class	Drugs	Mechanism of Action	Clinical Use
Surfactant Therapy	Exogenous surfactants (e.g., Beractant, Poractant alfa)	Replace deficient surfactant to improve lung compliance	Treatment of respiratory distress syndrome and ARDS
Corticosteroids	Betamethasone, Dexamethasone	Reduce inflammation and improve lung function	Severe ARDS cases where inflammation is a significant factor
Antibiotics	Ampicillin, Gentamicin	Treat or prevent bacterial infections	Prophylactic or therapeutic use as indicated
Diuretics	Furosemide, Chlorothiazide	Reduce fluid overload and manage pulmonary edema	Adjunctive therapy to maintain fluid balance
Inhaled Nitric Oxide	Nitric oxide	Vasodilation in	Improve oxygenation

(iNO)		pulmonary circulation	in severe cases of ARDS
Analgesics/Sedatives	Morphine, Midazolam	Manage pain and sedation during mechanical ventilation	Ensure patient comfort and reduce agitation
Prostaglandins	Prostaglandin E1 (Alprostadil)	Vasodilation, improving pulmonary blood flow	Supportive therapy for pulmonary hypertension

COMPLICATIONS

Preterm infants who suffer from Acute Respiratory Distress Syndrome (ARDS) may have a range of difficulties as a result of the severe respiratory and systemic effects it has on their delicate physiology. Among the typical complications are.

1. **Ventilator-Associated Lung Injury (VALI)**
   - The act of mechanically ventilating an individual can worsen lung damage, resulting in the development of conditions like atelectrauma (repeated opening and closing of alveoli), barotrauma (lung overdistension), and volutrauma (lung injury due to excessive tidal volumes).

2. **Pulmonary Hypertension**
   - ARDS may cause remodeling and constriction of the lungs, which raises pulmonary vascular resistance and causes pulmonary hypertension. This can cause right heart failure and complicate oxygenation.

3. **Fluid Imbalance**
   - In order to avoid fluid excess in ARDS, which can worsen pulmonary edema and impair oxygen exchange, fluid balance management is essential.

4. **Infections**
   - Preterm newborns with ARDS are more vulnerable to respiratory infections, such as bacterial pneumonia, which can exacerbate their respiratory state due to their impaired lung function.

5. **Neurodevelopmental Impairment**
   - Long-term neurodevelopmental abnormalities, such as cognitive deficiencies and cerebral palsy, can result from hypoxia and respiratory distress during the newborn period.

6. **Growth and Nutrition Issues**
   - Prolonged sickness and respiratory support may have an impact on growth and nutritional intake, which may result in underdevelopment and failure to thrive.

7. **Retinopathy of Prematurity (ROP)**:
   - ROP, a disorder that affects the formation of blood vessels in the retina of preterm newborns, can be exacerbated by oxygen treatment, which is frequently required in the management of ARDS.

8. **Long-Term Pulmonary Complications**
   - People who have survived acute respiratory distress syndrome (ARDS) may face persistent respiratory problems such as asthma, bronchopulmonary dysplasia, or recurrent respiratory infections.

9. **Psychological and Emotional Impact**
   - Extended hospital stays and medical procedures can have an adverse effect on the link between newborns and parents and cause psychological strain for both families and infants.

Careful monitoring, cautious breathing techniques to reduce lung damage, infection control procedures, nutritional assistance, and all-encompassing multidisciplinary care are all part of the prevention and early management of problems in acute respiratory distress syndrome (ARDS). It is crucial to do close follow-up after discharge in order to check for long-term effects and administer the necessary treatments.[23,24,25]

PREVENTION STRATEGIES

Several tactics are used to lower the risk factors that lead to the development of Acute Respiratory Distress Syndrome (ARDS) in preterm newborns. The following are important preventative techniques.

Antenatal Strategies

1. **Antenatal Corticosteroid Administration**
   - By accelerating fetal lung maturation, corticosteroids (such as betamethasone or dexamethasone) can help pregnant women at risk of preterm delivery (before 34 weeks gestation) experience a decreased risk of respiratory distress syndrome (RDS) and possibly acute respiratory distress syndrome (ARDS)
2. **Avoiding Premature Delivery**
   - By preventing preterm labor with the right prenatal care and treatments, the incidence of ARDS linked to prematurity can be decreased.

Intrapartum and Immediate Postnatal Strategies

1. **Careful Management of Delivery**
   - Making sure that the delivery procedure is calm and managed in order to reduce birth trauma and issues that might cause respiratory distress.
2. **Delayed Cord Clamping**
   - Permitting a delayed cord clamping might enhance placental transfusion and lower the chance of respiratory issues, like as acute respiratory distress syndrome (ARDS).

Neonatal Intensive Care Unit (NICU) Strategies

1. **Gentle Ventilation Strategies**
   - Lung damage that might result in ARDS can be avoided by implementing lung-protective ventilation techniques as soon as possible after delivery and during the course of any respiratory assistance that follows.
2. **Surfactant Administration**
   - Severe respiratory compromise and the subsequent development of ARDS can be avoided by giving exogenous surfactant to preterm babies at risk of RDS as soon as possible.
3. **Infection Prevention**
   - Use of personal protective equipment, good hand hygiene, and prophylactic medicines when necessary can all help lower the risk of infections that can lead to acute respiratory distress syndrome (ARDS).
4. **Fluid Management**
   - Vigilantly keeping an eye on and controlling the fluid balance to avoid fluid overload, which can worsen respiratory distress and cause pulmonary edema.
5. **Nutritional Support**
   - Enough nourishment, including parenteral nutrition where required, to promote development and reduce the stress reaction brought on by disease.
6. **Early Recognition and Treatment of Complications**
   - Timely identification of factors that increase the risk of acute respiratory distress syndrome (ARDS), such as meconium aspiration syndrome or congenital infections, and prompt action can lessen the degree of respiratory distress.

Postnatal Follow-Up and Care

1. **Long-Term Respiratory Follow-Up**
   - Consistent observation of respiratory development and function to identify and treat any new lung issues at an early stage.
2. **Support for Families**
   - Educating and assisting families with the care of infants, identifying respiratory distress symptoms, and guaranteeing that care continues after discharge.[26,27,28,29]

RESEARCH AND FUTURE DIRECTIONS

In order to enhance outcomes and lower complications, research and future approaches in the care of Acute Respiratory Distress Syndrome (ARDS) in preterm newborns center on many important areas.

1. **Early Diagnosis and Monitoring**
   - Creating biomarkers that are sensitive enough and imaging methods that can detect ARDS in preterm newborns at an early age. Regular monitoring of oxygenation and respiratory parameters to quickly identify worsening.
2. **Optimal Ventilation Strategies**
   - Improving ventilation techniques and approaches to reduce lung damage, such as developing lung-protective ventilation plans customized for prematurely born infants. For improved synchronization and lung protection, use neurally adjusted ventilatory assist (NAVA) and high-frequency oscillatory ventilation (HFOV).
3. **Pharmacological Interventions**
   - Investigating cutting-edge treatments, such as antioxidants, surfactant enhancers, and anti-inflammatory drugs, that target particular pathways of lung damage in ARDS. Assessing how corticosteroids can mitigate or prevent lung damage without having a negative impact on neurodevelopment.
4. **Supportive Care and Nutritional Strategies**
   - Strengthening nutritional assistance for preterm babies with ARDS in order to encourage lung development and healing. Improving infection control and fluid management practices, among other supportive care methods.
5. **Long-Term Outcomes and Neurodevelopment**
   - To improve management approaches, longitudinal research evaluating neurodevelopmental outcomes in preterm infants with ARDS are conducted. Improving functional results and long-term pulmonary consequences to enhance quality of life.
6. **Personalized Medicine Approaches**
   - Customizing treatment plans based on traits unique to each patient, such as a genetic predisposition and therapy response. Applying precision medicine techniques to reduce problems and maximize results.
7. **Multidisciplinary Collaborations and Data Sharing**
   - Encouraging cooperation to exchange data and conclusions amongst investigators, physicians, and organizations. Encouraging uniform policies and procedures to improve uniformity in the treatment of ARDS in various hospital environments.[30,31,32]

CONCLUSION

Preterm babies' particular physiological vulnerabilities and developmental immaturity provide a complicated and hard therapeutic environment for Acute Respiratory Distress Syndrome (ARDS). Important details on ARDS in preterm newborns, including as its epidemiology, pathogenesis, clinical presentation, diagnosis, treatment options, and long-term consequences, have been highlighted in this study. This review has highlighted the multidimensional character of ARDS in this vulnerable patient group, ranging from epidemiological discoveries revealing higher vulnerability in the preterm population to advances in understanding the molecular pathways driving lung damage. Clinical diagnosis is still difficult, requiring new biomarkers and improved criteria for early identification and prediction. Promising pathways for improving outcomes are provided by management measures, which range from improved breathing techniques to novel medicines such as regenerative medicine approaches. However, difficulties still exist, especially when it comes to striking a balance between therapeutic efforts to lessen lung damage and iatrogenic harm.

Future prospects are quite promising for the integration of precision medicine techniques based on individual genetic profiles and biomarker signatures. In order to improve clinical care for preterm children suffering by ARDS, collaborative research initiatives that take use of multicenter studies and technology developments in imaging and non-invasive monitoring will be essential. In the end, this analysis emphasizes how important it is for multidisciplinary teams to keep working together and being innovative in both clinical and research settings. We may work to improve outcomes and quality of life for preterm babies impacted by ARDS by filling up knowledge gaps and supporting evidence-based practices.

REFERENCES

1. Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, Herridge M, Randolph AG, Calfee CS. Acute respiratory distress syndrome. Nat Rev Dis Primers, 2019 Mar 14; 5(1): 18.
2. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. *Lancet*, 1967; 2: 319–323.
3. Aronson K, Rajwani K. The acute respiratory distress syndrome: a clinical review. J Emerg Crit Care Med, 2017; 1: 25.
4. Walkey AJ, Summer R, Ho V, et al. Acute respiratory distress syndrome: epidemiology and management approaches. Clin Epidemiol, 2012; 4: 159-69.
5. Reuter S, Moser C, Baack M. Respiratory distress in the newborn. Pediatr Rev, 2014 Oct; 35(10): 417-28; quiz 429.
6. Edwards MO, Kotecha SJ, Kotecha S. Respiratory distress of the term newborn infant. *Paediatr Respir Rev*, 2013; 14(1): 29–36.
7. Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA, 2016; 315: 788-800.
8. Villar J, Blanco J, Anon JM, et al. The ALIEN study: incidence and outcome of acute respiratory distress syndrome in the era of lung protective ventilation. Intensive Care Med, 2011; 37: 1932-41.
9. Matuschak GM, Lechner AJ. Acute lung injury and the acute respiratory distress syndrome: pathophysiology and treatment. Mo Med, 2010 Jul-Aug; 107(4): 252-8.
10. Kalikkot Thekkeveedu R, El-Saie A, Prakash V, Katakam L, Shivanna B. Ventilation-Induced Lung Injury (VILI) in Neonates: Evidence-Based Concepts and Lung-Protective Strategies. J Clin Med, 2022 Jan 22; 11(3): 557.
11. Ranieri VM, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA*, 2012; 307: 2526–2533.
12. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol, 2011; 6: 147-63.
13. Huppert LA, Matthay MA, Ware LB. Pathogenesis of Acute Respiratory Distress Syndrome. Semin Respir Crit Care Med, 2019 Feb; 40(1): 31-39.
14. Kaku S, Nguyen CD, Htet NN, et al. Acute Respiratory Distress Syndrome: Etiology, Pathogenesis, and Summary on Management. *Journal of Intensive Care Medicine*, 2020; 35(8): 723-737.
15. Core Concepts: Respiratory Distress Syndrome https: //publications.aap.org/neoreviews/article/10/7/e351/88336/Core-ConceptsRespiratory-Distress-Syndrome
16. Abdulnour RE, et al. Early intravascular events are associated with development of acute respiratory distress syndrome. A substudy of the LIPS-A clinical trial. *Am. J. Respir. Crit. Care Med*, 2018; 197: 1575–1585.
17. Weisman LE, Hansen TN. *Contemporary Diagnosis and Management of Neonatal Respiratory Diseases*. 3rd ed. Newton, PA: Handbooks in Health Care Co, 2003.
18. Aly H. Respiratory disorders in the newborn: identification and diagnosis. *Pediatr Rev*, 2004; 25(6): 201–208.
19. Fielding-Singh V, Matthay MA, Calfee CS. Beyond low tidal volume ventilation: treatment adjuncts for severe respiratory failure in acute respiratory distress syndrome. *Crit. Care Med*, 2018; 46: 1820–1831.
20. Calfee CS, Matthay MA. Nonventilatory treatments for acute lung injury and ARDS. *Chest*, 2007; 131: 913–920.
21. Wheeler AP, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. *N. Engl. J. Med*, 2006; 354: 2213–2224.
22. Mathai SS, Raju U, Kanitkar M. Management of Respiratory Distress in the Newborn. Med J Armed Forces India, 2007 Jul; 63(3): 269-72.
23. Medications for Respiratory Distress Syndrome https: //www.drugs.com/condition/respiratory-distress-syndrome.html
24. Fan E, et al. Physical complications in acute lung injury survivors: a two-year longitudinal prospective study. *Crit. Care Med*, 2014; 42: 849–859.
25. Antonelli M, Conti G, Moro ML, et al. Predictors of failure of noninvasive positive pressure ventilation in patients with acute hypoxemic respiratory failure: a multi-center study. Intensive Care Med, 2001; 27: 1718-28.
26. Banavasi H, Nguyen P, Osman H, Soubani AO. Management of ARDS - What Works and What Does Not. Am J Med Sci, 2021 Jul; 362(1): 13-23.
27. Spencer C, Neales K. Antenatal corticosteroids to prevent neonatal respiratory distress syndrome. We do not know whether repeated doses are better than a single dose. BMJ, 2000 Feb 5; 320(7231): 325-6.
28. Kalikkot Thekkeveedu R, El-Saie A, Prakash V, Katakam L, Shivanna B. Ventilation-Induced Lung Injury (VILI) in Neonates: Evidence-Based

Concepts and Lung-Protective Strategies. J Clin Med, 2022 Jan 22; 11(3): 557.
29. Keddissi JI, Youness HA, Jones KR, Kinasewitz GT. Fluid management in Acute Respiratory Distress Syndrome: A narrative review. Can J Respir Ther, 2018 Dec 5; 55: 1-8.
30. Bogdan RD, Bohiltea RE, Toma AI. Respiratory Follow Up of the Premature Neonates-Rationale and Practical Issues. J Clin Med, 2022 Mar 21; 11(6): 1746.
31. Nanchal RS, Truwit JD. Recent advances in understanding and treating acute respiratory distress syndrome. F1000Res, 2018 Aug 20; 7: F1000 Faculty Rev-1322.
32. Hee Chung E, Chou J, Brown KA. Neurodevelopmental outcomes of preterm infants: a recent literature review. Transl Pediatr, 2020 Feb; 9(Suppl 1): S3-S8.